PROSTATE CANCER PREDICTION BASED ON PCA3 EVALUATION
Authors:
V. Vyhnánková; M. Fedorko; M. Král; V. Študent; T. Jamaspishvili
Authors‘ workplace:
Urologická klinika FN Brno LF MU Brno
Published in:
Urol List 2011; 9(4): 43-48
Overview
New biomarkers of prostate cancer have been identified aiming to reduce the number of unnecessary biopsies as well as to increase the detection rate of prostate cancer. PCA3 as one of them, identified in 1999, is highly over-expressed in prostate cancer tissue. Evaluating PCA3 is supposed to help in guiding clinical decision towards biopsy in case of PSA 2,5–10 ng/ml („gray zone“) and where prostate cancer is suspect despite negative result of inicial biopsy. The article summarizes the current knowledge based on novel clinical trials regarding PCA3-based prostate cancer prediction and provides recommendation for use of PCA3 in common urological practice.
Key words:
prostate cancer, PCA3, PCA3 score, prostate biopsy
Sources
1. Boyle P, Ferlay J. Cancer incidence and mortality in Europe 2004. Ann Oncol 2005; 16(3): 481–488.
2. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58(2): 71–96.
3. Dorr VJ, Williamson SK, Stephens RL. An evaluation of prostate-specific antigen as a screening test for prostate cancer. Arch Intern Med 1993; 153(22): 2529–2537.
4. Heidenreich A, Bellmunt J, Bolla M et al. EAU guidelines on Prostate Cancer. In: EAU Guidelines, edition presented at the 25th EAU Annual Congress, Barcelona 2010.
5. Andriole GL, Crawford ED, Grubb RL 3rd et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360(13): 1310–1319.
6. Schröder FH, Hugosson J, Roobol MJ et al. ERSPC Investigators. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360(13): 1320–1328.
7. Loeb S, Catalona WJ. What is the role of digital rectal examination in men undergoing seriál screening of serum PSA levels? Nat Clin Pract Urol 2009; 6(2): 68–69.
8. Catalona WJ, Richie JP, Ahmann FR et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 1994; 151(5): 1283–1287.
9. Carter HB. Prostate cancers in men with low PSA levels-must we find them? N Engl J Med 2004; 350(22): 2292–2294.
10. Bussemakers MJ, van Bokhoven A, Gerald W et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 1999; 59(23): 5975–5979.
11. Marks LS, Bostwick DG. Prostate Cancer Specificity of PCA3 Gene Testing: Examples from Clinical Practice. Rev Urol 2008; 10(3): 176–181.
12. Day J, Jost M, Reynolds M et al. PCA3: From basic molecular science to the clinical lab. Cancer Letters 2011; 301(1): 1–6.
13. de la Taille A. Progensa™ PCA3 test for prostate cancer detection. Expert Rev Mol Diag 2007; 7(5): 491–497.
14. Bourdoumis A, Papatsoris A, Chrisofos M et al. The Novel Prostate Cancer Antigen 3 (PCA3) Biomarker. Int Braz J Urol 2010; 36(6): 665–669.
15. Mo S, Wei Ch, Kaiyuan Y et al. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population. Exp Mol Pat 2011; 90(1): 97–100.
16. Kirby RS, Fitzpatrick JM, Irani J. Prostate cancer diagnosis in the new millennium: strengths and weaknesses of prostate-specific antigen and the discovery and clinical evaluation of prostate cancer gene 3 (PCA3). BJU Int 2009; 103(4): 441–445.
17. Deras IL, Aubin SM, Blase A et al. PCA3: A molecular urine assay for predicting prostate biopsy outcome. J Urol 2008; 179(4): 1587–1592.
18. Ruiz-Aragón J, Márquez-Peláez S. Assessment of the PCA3 test for prostate cancer diagnosis: A systematic review and meta-analysis. Actas Urol Esp 2010; 34(4): 346–355.
19. Vlaeminck-Guillem V, Ruffion A, Andre J et al. Urinary prostate cancer 3 test: toward the age of reason? Urology 2010; 75(2): 447–451.
20. Fradet Y, Saad F, Aprikian A et al. UPM3, a new molecular urine test for the detection of prostate cancer. Urology 2004; 64(2): 311–315.
21. Marks LS, Fradet Y, Deras IL et al. PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy. Urology 2007; 69(3): 532–535.
22. Aubin S, Reid J, Sarno M et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: Validation in the placebo arm of the dutasteride REDUCE trial. J Urol 2010; 184(5): 1947–1952.
23. Ploussard G, Haese A, van Poppel H et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies? BJU Int 2010; 106(8): 1143–1147.
24. Haese A, de la Taille A, van Poppel H et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54(5): 1081–1088.
25. Salami S, Schmidt F, Laxman B et at. Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Onc 2011 [Epub ahead of print].
26. Roobol MJ, Schroder FH, van Leeuwen P et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol 2010; 58(4): 475–480.
27. Shappell SB, Fulmer J, Arguello D et al. PCA3 Urine mRNA Testing for Prostate Carcinoma: Patterns of Use by Community Urologists and Assay Performance in Reference Laboratory Setting. Urology 2009; 73(2): 363–368.
28. Roobol M, Schröder F, van Leenders G et al. Performance of Prostate Cancer Antigen 3 (PCA3) and Prostate-Specific Antigen in Prescreened Men: Reproducibility and Detection Characteristics for Prostate Cancer Patients with High PCA3 Scores (≥ 100). Eur Urol 2010; 58(6): 893–899.
29. Hessels D, van Gils M, Hooij O et al. PredictiveValue of PCA3 in Urinary Sediments in Determining Clinico-Pathological Characteristics of Prostate Cancer. Prostate 2010; 70(1): 10–16.
30. Nakanishi H, Groskopf J, Fritsche HA et al. PCA3 Molecular Urine Assay Correlates With Prostate Cancer Tumor Volume: Implication in Selecting Candidates for Active Surveillance. J Urol 2008; 179(5): 1804–1809.
31. Wang R, Chinnaiyan AM, Dunn RL et al. Rational Approach to Implementation of Prostate Cancer Antigen 3 Into Clinical Care. Cancer 2009; 115(17): 3879–3886.
32. Biganti A. Editorial Comment on: Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. Eur Urol 2009; 56(4): 667.
33. Groskopf J, Aubin S, Deras IL et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 2006; 52(6): 1089–1095.
34. Remzi M, Haese A, van Poppel H et al. Follow-up of men with an elevated PCA3 score and a negative biopsy: does an elevated PCA3 score indeed predict the presence of prostate cancer? BJU Int 2010; 106(8): 1138–1142.
Labels
Paediatric urologist UrologyArticle was published in
Urological Journal
2011 Issue 4
Most read in this issue
- PROSTATE CANCER PREDICTION BASED ON PCA3 EVALUATION
- RENAL CANCER EARLY DETECTION, THE ROLE OF TUMOUR MARKERS IN FURTHER DIAGNOSTIC, THERAPEUTIC AND PROGNOSTIC STRATEGY
- SURGICAL MANAGEMENT OF THE RENAL CANCER WITH THE TUMOR THROMBUS IN THE VENOUS SYSTEM T3B AND T3C
- COMBINATION THERAPY OF BENIGN PROSTATIC HYPERPLASIA – CLINICAL APLLICATIONS